Stifel analyst Stephen Willey downgraded Vor Bio (VOR) to Hold from Buy with a price target of 30c, down from $5, following the company’s decision to explore a range of strategic alternatives in an effort to maximize shareholder value. The decision reflects a combination of both clinical data evaluated to date and the challenging financing environment currently characterizing the biotech sector, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR: